Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Immunome, Inc. (IMNM) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Immunome, Inc. (IMNM), most recent 12 months reported: revenue $0, net loss $254.32M, free cash flow -$219.09M. Latest balance sheet on file: liquid cash $520M. From SEC filings. Others in Pharmaceutical Preparations: Hepion Pharmaceuticals, Inc. · WEREWOLF THERAPEUTICS, INC. · TuHURA BIOSCIENCES, INC./NV · IMMIX BIOPHARMA, INC. · Imunon, Inc. · Immuneering Corporation · Immunic, Inc. · Indaptus Therapeutics, Inc.

Stock screener

Watchlist